Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

acromegaly

This page shows the latest acromegaly news and features for those working in and with pharma, biotech and healthcare.

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA

Recent estimates put the prevalence of acromegaly at between 115 and 295 cases per million, around double earlier estimates because of a higher-than-thought prevalence of pituitary adenomas. ... Physicians now have a new acromegaly therapy that provides

Latest news

  • FDA approves Ipsen drug to treat rare tumours FDA approves Ipsen drug to treat rare tumours

    Somatuline Depot is already available in the US as a treatment for a condition known as acromegaly where patients overproduce a growth hormone. .

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    This first approval of Signifor in acromegaly marks a much needed advance in the treatment of this rare disease.". ... Signifor LAR has been submitted worldwide for the treatment of acromegaly, with an application filed in the US earlier this year, said

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    Could add to Signifor’s indications. A phase III trial of Novartis' somatostatin analogue Signifor has suggested it could be effective for the growth hormone disorder acromegaly. ... may offer benefit for acromegaly patients whose disease is not fully

  • Shining a light on orphan medicines Shining a light on orphan medicines

    Patient registries such as the Pfizer International Growth Study (KIGS), Pfizer International Metabolic Study (KIMS), Pfizer's ACROSTUDY database for patients with acromegaly, and Shire HGT's Fabry Outcome Survey (FOS)

  • Roche licenses Chiasma’s acromegaly drug in $595m deal Roche licenses Chiasma’s acromegaly drug in $595m deal

    The licensing deal - valued at up to $595m - is for Octreolin (oral octreotide acetate), a drug candidate which which is currently in phase III testing for acromegaly and also in development ... Our oral octreotide has the potential to improve the

More from news
Approximately 4 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    The drug treats the hormonal disorder acromegaly and neuroendocrine tumours (NETs), a rare form of cancer.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    Meanwhile, Chiasma remains committed to the development of an oral form of the peptide drug octreotide - a growth hormone inhibitor used to treat acromegaly - despite Roche's decision to hand back

  • Pharma deals in May 2015 Pharma deals in May 2015

    Staying with rare diseases, Cortendo closed a deal with Antisense Therapeutics for ATL 1103 in acromegaly. ... 116. Antisense/ Cortendo. Licence agreement. To develop and market ATL 1103 [P2 ready] in endocrine disorders including acromegaly.

  • Pharma deals during August 2014 Pharma deals during August 2014

    Not all planned alliances however run a smooth course as was the case with the Chiasma/ Roche $600m commercial agreement for Octreolin, the orally acting acromegaly drug.

  • Pharma deals during September 2013 Pharma deals during September 2013

    from Camarus, paying an undisclosed milestone included in their $700 million deal signed two years ago for the indications acromegaly and neuroendocrine tumours.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Kirsti Gjellan swaps Pfizer for Sobi Kirsti Gjellan swaps Pfizer for Sobi

    The site opened in 2009 to produce the active ingredients for growth hormone Genotropin (somatropin) and the acromegaly treatment Somavert (pegvisomant).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Communiqué Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Quick links

Infographics

Multimedia